The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis

  title={The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis},
  author={Michael S. Garshick and James A. Underberg},
  journal={Current Atherosclerosis Reports},
Purpose of ReviewMany guidelines exist for the use of statins in the primary prevention of atherosclerotic cardiovascular disease (ASCVD). Few have focused on disease specific states that predispose to ASCVD. This review is intended to focus on the recommendations and evidence in inflammatory diseases that predispose to an increased risk of ASCVD beyond what conventional cardiac risk scores would predict.Recent FindingsCertain autoimmune inflammatory diseases such as rheumatoid arthritis (RA… 
Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention.
The intricate interplay of SLE-specific properties that contribute to atherosclerosis and CVD within this population are explored, as well as screening methods and possible therapies.
Cardiovascular disease in patients with psoriatic arthritis: correlation or causation?
This document is intended to help clarify the role of data protection in the operation of this website and its implications for individual users.
Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1
The data demonstrate a previously unappreciated role of platelets in psoriasis and endothelial cell inflammation and suggests that aspirin may be effective in improving vascular health in patients with Psoriasis.
Simvastatin promotes endothelial dysfunction by activating the Wnt/β-catenin pathway under oxidative stress
It was hypothesized that simvastatin may promote ER stress by facilitating LRP6 phosphorylation and the subsequent activation of the Wnt/β-catenin pathway, thereby enhancing H2O2-induced ED.
Biochanin A Mitigates Atherosclerosis by Inhibiting Lipid Accumulation and Inflammatory Response
Results showed that administration of BCA promoted reverse cholesterol transport (RCT), improved plasma lipid profile, and decreased serum proinflammatory cytokine levels and atherosclerotic lesion area in apoE−/− mice fed a Western diet, suggesting that BCA is protective against atherosclerosis by inhibiting lipid accumulation and inflammatory response through the PPARγ/LXRα and PParγ/HO-1 pathways.
Epigenetic mechanisms underlying the benefits of flavonoids in cardiovascular health and diseases: are long non-coding RNAs rising stars?
Based on a review of research on the modulatory effects of lncRNAs and their roles in mediating cellular processes, flavonoids might facilitate a significant epigenetic modification as part of their tissue-/cell-related biological effects.
MicroRNA-30-3p Suppresses Inflammatory Factor-Induced Endothelial Cell Injury by Targeting TCF21
The results reveal that miR-30-5p suppresses the progression of atherosclerosis through targeting TCF21 in vitro and may be a potential biomarker or therapeutic target in Atherosclerosis.
Andrographolide in atherosclerosis: integrating network pharmacology and in vitro pharmacological evaluation
The present study successfully predict AG’s potential targets and pathways in atherosclerosis and illustrate the mechanism of action.
Influence of atorvastatin therapy on biological markers and cardiovascular risk in patients with chronic lymphocytic leukemia in remission
Матеріали та методи. У дослідження залучили 157 пацієнтів із хронічною лімфоцитарною лейкемією в частковій або повній ремісії. Аторвастатин у дозі 20 мг на добу (n = 50) і 40 мг на добу (n = 18)


Statins for prevention of cardiovascular disease in systemic lupus erythematosus.
Prescription of statins are recommended in SLE patients with increased cardiovascular risk according to the current recommendations for cardiovascular risk management in rheumatoid arthritis.
Management of cardiovascular disease in patients with psoriasis
The evidence associating psoriasis with CV disease, as well as the pharmacological and non-pharmacological treatment of CV risk factors including the CV effects of anti-psoriatic therapy and vice versa are described.
Statins for primary prevention of cardiovascular disease
Five authoritative guidelines, including the recent publication from the US Preventive Services Task Force, cover this issue and agree that statins are appropriate in patients with a high risk of cardiovascular disease—for example, people over 40 with diabetes but with considerable divergence in the details.
The impact of psoriasis on 10-year Framingham risk.
Cardiovascular Mortality in Psoriasis and Psoriatic Arthritis: Epidemiology, Pathomechanisms, Therapeutic Implications, and Perspectives
Effective long-term anti-inflammatory, disease-modifying therapy may contribute to reducing patients’ cardiovascular risk, and secondary and tertiary care physicians need to consider a more comprehensive treatment approach, including aspects of lifestyle intervention.
Cardiovascular risk assessment in rheumatoid arthritis – controversies and the new approach
This review discusses the efficiency of a new Pooled Cohort Equation and other calculators in the general and RA population and creates RA-specific risk calculators, such as the Expanded Cardiovascular Risk Prediction Score for RA.
Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study
Cardiovascular risk should be addressed with all patients affected by psoriasis, PsA or RA and an interaction between disease status and disease-modifying antirheumatic drug (DMARD) use is hypothesised.